Experimental drug cocktail targets genetic driver in Tough-to-Treat cancers

NCT ID NCT06496568

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing the safety and initial effectiveness of a new drug called inavolisib, both alone and combined with two existing immunotherapy drugs (atezolizumab and pembrolizumab). It's for people with advanced head and neck cancer and other cancers that have a specific genetic change called a PIK3CA mutation. The main goal is to see how well the treatments are tolerated and to find the right dose before larger studies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

BC Cancer Vancouver Centre
RECRUITING

Vancouver, British Columbia, V5Z 4E6, Canada
California Cancer Associates for Research & Excellence, Inc.
WITHDRAWN

San Marcos, California, 92069, United States
Jewish General Hospital
RECRUITING

Montreal, Quebec, H3T 1E2, Canada
Moores Cancer Center at UC San Diego Health
WITHDRAWN

La Jolla, California, 92093, United States
Princess Margaret Cancer Center
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Seoul National University Hospital
WITHDRAWN

Seoul, 03080, South Korea
Vanderbilt-Ingram Cancer Ctr
RECRUITING

Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.

PIK3CA-MUTATED CANCERS